Formycon’s Keytruda Biosimilar Enters Phase I Clinical Trial
Phase III Study In NSCLC Patients Is Expected To Begin Shortly
One of the self-proclaimed frontrunners in the pembrolizumab biosimilar race, Formycon, has initiated the first clinical trial for its FYB206 candidate. Meanwhile, Celltrion submits a Phase III trial application to the FDA, expecting “limitless” sales potential for its CT-P51 version.
